HomeCompareVUPPF vs ABBV

VUPPF vs ABBV: Dividend Comparison 2026

VUPPF yields 5.21% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.4K in total portfolio value
10 years
VUPPF
VUPPF
● Live price
5.21%
Share price
$109.49
Annual div
$5.70
5Y div CAGR
-8.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.9K
Annual income
$259.73
Full VUPPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VUPPF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVUPPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VUPPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VUPPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VUPPF
Annual income on $10K today (after 15% tax)
$442.51/yr
After 10yr DRIP, annual income (after tax)
$220.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,835.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VUPPF + ABBV for your $10,000?

VUPPF: 50%ABBV: 50%
100% ABBV50/50100% VUPPF
Portfolio after 10yr
$63.6K
Annual income
$12,515.75/yr
Blended yield
19.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VUPPF
No analyst data
Altman Z
-0.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VUPPF buys
0
ABBV buys
0
No recent congressional trades found for VUPPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVUPPFABBV
Forward yield5.21%3.06%
Annual dividend / share$5.70$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.8%40.6%
Portfolio after 10y$24.9K$102.3K
Annual income after 10y$259.73$24,771.77
Total dividends collected$3.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VUPPF vs ABBV ($10,000, DRIP)

YearVUPPF PortfolioVUPPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,175$474.78$11,550$430.00$375.00ABBV
2$12,409$452.22$13,472$627.96$1.1KABBV
3$13,706$428.02$15,906$926.08$2.2KABBV
4$15,068$402.94$19,071$1,382.55$4.0KABBV
5$16,501$377.57$23,302$2,095.81$6.8KABBV
6$18,008$352.41$29,150$3,237.93$11.1KABBV
7$19,596$327.81$37,536$5,121.41$17.9KABBV
8$21,272$304.05$50,079$8,338.38$28.8KABBV
9$23,043$281.32$69,753$14,065.80$46.7KABBV
10$24,915$259.73$102,337$24,771.77$77.4KABBV

VUPPF vs ABBV: Complete Analysis 2026

VUPPFStock

VP Bank AG, together with its subsidiaries, provides asset management and investment consulting services for private and institutional investors in Liechtenstein, rest of Europe, and internationally. The company offers wealth management and planning services; personal, foreign currency, vested benefits, current, and savings accounts; bank cards for card payments and cash withdrawals; e-banking and e-post services; and transaction slips, account statements, and interest statements. It also provides Lombard loan, such as fixed advance/fixed interest loan and overdraft facility; and real estate financing services, which include fixed-rate mortgage, forward fixed-rate mortgage, money market mortgage, and construction loans, as well as services related to external asset managers, and trustees and lawyer; business financing services comprising fixed adavnces, loans, and current account overdrafts. In addition, the company offers e-banking, investment advisory, custodian bank, and private label fund services. VP Bank AG was founded in 1956 and is headquartered in Vaduz, Liechtenstein.

Full VUPPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VUPPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VUPPF vs SCHDVUPPF vs JEPIVUPPF vs OVUPPF vs KOVUPPF vs MAINVUPPF vs JNJVUPPF vs MRKVUPPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.